Data / Form D filings / Kairos Pharma, LTD.
Kairos Pharma, LTD.: Form D filings
Kairos Pharma, LTD., a pharmaceuticals company in Los Angeles, CA, filed 2 Form D notices with the SEC between 2023 and 2025. The latest, on January 28, 2025, reports $3.5 million sold of a $8.8 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 2355 WESTWOOD BLVD., #139, Los Angeles, CA, 90064
- Phone
- (310) 948-2356
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1962011
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 28, 2025 | New notice | $8,750,000 | $3,497,500 | $5,252,500 | 1 | Jan 16, 2025 | sec.gov |
| Apr 27, 2023 | New notice | $3,000,000 | $675,000 | $2,325,000 | 9 | Jun 30, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Hyun W. Bae | Director | |
| Neil S. Bhowmick | Executive Officer | |
| John S. Yu | Executive Officer, Director | |
| Hansoo Michael W. Keyoung | Director | |
| Ramachandran S. Murali | Executive Officer | |
| Doug S. Samuelson | Executive Officer | |
| Rahul W. Singhvi | Director |
Other pharmaceuticals companies in California that filed recently
- Anvion Bio, Inc. $100,000 · Oct 7, 2026
- Aqur Biosciences, Inc. $1.5 million · Sep 18, 2026
- BTB Therapeutics, Inc. $8.9 million · Aug 12, 2026
Every Form D from the week of Jan 27, 2025 · All recent filings in California · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Kairos Pharma, LTD. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.